Selank
10mg nasal
Short neuropeptide investigated in neurocognitive signaling and stress-response pathway research.
$40.00
Explore → Shop
VIEW ALL FOCUS
FOCUS
Semax
10mg nasal
$40.00
FOCUS
Semax10mg nasal
$40.00
1
7 available · Ships within 48 hours
- Third-Party TestedThird-Party Tested
- Cold-Chain HandledCold-Chain Handled
- Concierge SupportConcierge Support
Questions about this compound, specifications, or documentation?
Speak with the ConciergeACTH(4-10) heptapeptide analog referenced in published literature investigating BDNF expression and monoaminergic pathway biology.
- Neurocognitive signaling research
- Nasal-route research form factor
- Cold-chain handled, third-party tested
VIEW BATCH COA
Independent lab verification · current batch
- THIRD-PARTY TESTED
- COLD-CHAIN HANDLED
- TRACKED SHIPPING
- QUALITY-FOCUSED SOURCING
SPECIFICATIONS
- Product
- Semax
- Strength
- 10mg nasal
- Vial Size
- 10mg nasal per vial
- SKU
- VLR-SEM-10
- Batch / Lot
- Current batch listed on COA
- Storage
- Refrigerate 2–8°C · protect from light
- Form
- Lyophilized powder
RESEARCH USE ONLY
Sold strictly for laboratory and research purposes — never for human consumption, food, drug, or cosmetic use. 21+ only. A standard we hold ourselves to, not just the law.
EDUCATIONAL OVERVIEW
About this compound
Context, not noise — what the research actually says.
WHAT IT IS
A nasal research peptide investigated in neurocognitive signaling and BDNF-related pathway literature.
FOCUS
KEY BENEFITS
- Studied in neurocognitive signaling pathways
- Investigated in stress-response pathway research
- Referenced in neurotrophic and synaptic-plasticity literature
COMMON USES
- Neurocognitive signaling research
- Stress-response pathway studies
- Discreet daily research applications
THINGS TO KNOW
- Nasal-route research peptide — store refrigerated
- Protect from light; do not freeze
- Research use only — not for human consumption
RELATED COLLECTION
Focus Research Collection
Pairs with Selank — Two short neuropeptides referenced together in neurocognitive signaling literature.
VIEW COLLECTION
COLLECTION PRICE
$70.00
STORAGE
Cold-chain handling
REFRIGERATED
Store unopened at 36–46°F (2–8°C).
RECONSTITUTED
Keep refrigerated. Do not freeze.
PROTECT FROM LIGHT
Original packaging until use.
Store unopened vials refrigerated at 36–46°F (2–8°C). After reconstitution, keep refrigerated and use within the timeframe specified by your laboratory practice. Protect from light. Do not freeze reconstituted solution.
SHIPPING
Shipping information
Insulated, tracked, and handled with care from our facility to yours.
PROCESSING
Ships within 48 hours of order confirmation.
COLD-CHAIN
Insulated packaging with ice packs for temperature-sensitive compounds.
TRACKED & INSURED
Tracking provided. Domestic delivery typically 2–5 business days.
Local pickup is available by appointment for customers in the Phoenix, Arizona area. See the full shipping policy for details, accepted payment methods, and scheduling.
FAQ
Common questions
SCIENTIFIC RESEARCH OVERVIEW · SRO
Scientific Research Overview
A structured summary of published scientific literature on this compound — provided for educational reference only.
Neuroscience Research
RESEARCH SNAPSHOT
- Research Category
- Investigational synthetic ACTH(4-10) heptapeptide analogue
- Biological Targets
- Brain-Derived Neurotrophic Factor (BDNF)
- Melanocortin system
- Central nervous system signaling
- Primary Areas of Research
- BDNF-pathway signaling · Neurotrophic-factor biology · Melanocortin-system signaling · Neurocognitive research · Cerebrovascular research · Monoaminergic-system modulation
- Current Stage of Research
- Preclinical and Human Clinical Research
WHAT IS SEMAX?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) analogue of the adrenocorticotropic hormone (ACTH) fragment 4-10, investigated in the scientific literature for its effects on neurotrophic signaling, melanocortin pathways, and central nervous system activity. It has been studied in preclinical rodent models and in human clinical research, particularly in contexts involving cerebrovascular and cognitive impairment.
PRIMARY AREAS OF RESEARCH
- BDNF-pathway signaling
- Neurotrophic-factor biology
- Melanocortin-system signaling
- Neurocognitive research
- Cerebrovascular research
- Monoaminergic-system modulation
- Published studies have investigated dose- and time-dependent increases in BDNF protein and trkB receptor expression in the hippocampus, basal forebrain, and other brain regions of rodent models.
- Research suggests effects on neurocognitive parameters, including attention, memory-related tasks, and learning markers in preclinical and early human studies.
- Current evidence indicates modulation of melanocortin and monoaminergic pathways, as well as changes in dopaminergic, serotonergic, and noradrenergic system markers in reported datasets.
- Investigators have observed neuroprotective and cerebrovascular-related outcomes in clinical studies of ischemic stroke and cerebrovascular insufficiency.
Semax is being studied for its ability to influence melanocortin receptors and to increase expression of brain-derived neurotrophic factor (BDNF) and its receptor trkB in central nervous system tissue. Current evidence indicates that these effects may support neurotrophic signaling, synaptic plasticity, and neuronal survival pathways. Published work also suggests interactions with dopaminergic, serotonergic, and noradrenergic systems, along with changes in gene-expression patterns related to stress response and neuroprotection.
CURRENT AREAS OF INVESTIGATION
- Neurocognitive Research
- BDNF Signaling
- Healthy Aging
- Cellular Repair
- Stress Response
- Neuroprotection
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. View source
- Dolotov OV, Inozemtseva LS, Savelieva EL, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(4):1167–1177. View source
- Kost NV, Sokolov OY, Gabaeva MV, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Dokl Biol Sci. 2007;412:60–62. View source
- Medvedeva LV, Ivanov VB, Bobkova NV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003;392:423–425. View source
- Gusev EI, Skvortsova VI, Maksakova GA, et al. [The efficacy of semax in the treatment of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6):67–73. View source
RESEARCH STATUS
This compound continues to be investigated in preclinical and/or clinical research. Scientific understanding continues to evolve as additional studies are published.
RESEARCH DISCLAIMER
For laboratory research use only. This information summarizes published scientific literature for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
RELATED · FOCUS
More from this pillar
RESEARCH DISCLAIMER
All VELOR compounds are sold strictly for laboratory and research purposes only. They are not intended for human consumption, ingestion, or any food, drug, cosmetic, or therapeutic use. By purchasing, you confirm you are 21+ and a qualified researcher or research institution. Statements have not been evaluated by the FDA.
FOCUS
Semax
$40.00
1